Feng Ren

This inventor holds 24 USPTO granted patents and 43 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Insilico Medicine IP Limited, Glaxosmithkline Intellectual Property Development Limited, Shanghai Medicilon Inc.. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Feng Ren. Retrieved from https://idiyas.com/inventor/feng-ren-jmsvduqh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 43)

% Patents Active = 58.3

CIPO Patents = 1 (Patent Applications = 22)

EPO Patents = 3 (Patent Applications = 54)

Average Co-Inventor Count = 4.9

ph-index = 2

Forward Citations = 12(Granted Patents)

Location History:

Shenzhen, CN (2007)
Shanghai, CN (2012 - 2024)

Company Filing History:

10 out of 40

Insilico Medicine IP Limited

patents

7 out of 242

Glaxosmithkline Intellectual Property Development Limited

patents

4 out of 4

Shanghai Medicilon Inc.

patents

4. 3 out of 3

Medicilon Preclinical Research (Shanghai) LLC.

Huawei Technologies Co., Limited

patents

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

Indole Derivative

Pyrrolopyrazole

PHD Inhibitors

LRRK2 Inhibitors

Gastric Acid Diseases

Diacylglycerol Kinase

Methionine Adenosyltransferase

TEAD Inhibitors

CXCR2 Inhibitors

Heterocyclic Compounds

Oxadiazole Compounds

SARS-CoV-2 Inhibitors

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760036 - Inhibitors of KIF18A and uses thereof (2026-10-13),

2. 12486229 - Indole derivative and application thereof (2025-12-02),

3. 12404276 - Substituted pyrrolo[3,4-c]pyrazoles for treating gastric acid-related diseases (2025-09-02),

4. 12391696 - Pyrrolopyrazole derivatives, preparation method thereof and application thereof in medicine (2025-08-19),

5. 12378252 - Pyrrolopyrazole derivatives, preparation method thereof and application thereof in medicine (2025-08-05),

6. 12209101 - Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof (2025-01-28),

7. 12103915 - TEAD inhibitors and methods of uses thereof (2024-10-01),

8. 12091406 - Lysine acetyltransferase 6A (KAT6A) inhibitors and uses thereof (2024-09-17),

9. 12077538 - Diacylglycerol kinase (DGK) alpha inhibitors and uses thereof (2024-09-03),

10. 12071443 - Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof (2024-08-27),

11. 11999713 - Methionine adenosyltransferase 2a (MAT2A) inhibitors and uses thereof (2024-06-04),

12. 11780854 - Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof (2023-10-10),

13. 11731987 - Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof (2023-08-22),

14. 11731944 - SARS-CoV-2 inhibitors for treating coronavirus infections (2023-08-22),

15. 11034696 - Compounds for inhibiting LRRK2 kinase activity (2021-06-15),

Title: The Innovative Mind of Feng Ren

Introduction

Feng Ren, a prominent inventor located in Shanghai, China, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 18 patents. His work primarily focuses on advancements that address critical health issues, showcasing his commitment to innovation and improvement in medical treatments.

Latest Patents

Among Feng Ren's latest patents are groundbreaking advancements in the treatment of anemia and modulation of critical biological pathways. One notable patent is for Prolyl hydroxylase domain-containing protein (PHD) inhibitors, which details pharmaceutical compositions that utilize these inhibitors to treat anemia effectively. Another significant patent involves TEAD inhibitors, offering novel compounds and methods for modulating or inhibiting TEAD, along with pharmaceutical compositions that incorporate these inhibitors for potential therapeutic applications.

Career Highlights

Feng Ren has had a successful career, working with prominent companies in the pharmaceutical industry, including Insilico Medicine IP Limited and GlaxoSmithKline Intellectual Property Development Limited. His experience in these organizations has contributed immensely to his innovative capacity and understanding of advanced research methodologies.

Collaborations

Throughout his career, Feng has collaborated with accomplished professionals in his field, including Xiao Ding and Xichen Lin. These collaborations have led to groundbreaking research and development that has the potential to transform current medical practices.

Conclusion

Feng Ren stands out as a dedicated inventor whose work spans several critical areas in pharmaceuticals. With a focus on innovative solutions to health challenges, his contributions continue to pave the way for advancements in medical treatments, marking him as a significant figure in the realm of scientific innovation.

Profile summary based on public USPTO records.